CardioExchange Archive

CardioExchange, an NEJM practice community for medical professionals dedicated to improving cardiac patient care, was active from 2009 to 2015. CardioExchange fostered discussion between clinicians from across the globe.

March 4th, 2015

Genetic Screening Test Could Identify People More Likely To Benefit From Statins

A genetic risk score can identify people at high risk for coronary disease, according to a new report in the Lancet. The score can also help find those who are most likely to benefit from statin therapy.

The genetic risk score, derived from 27 single-nucleotide polymorphisms (SNPs), successfully identified individuals at highest risk for a cardiac event within a study population of some 50,000 people who participated in a large community-based cohort study or one of four randomized controlled statin trials. People in the highest quintile of genetic risk had a 70% greater risk for coronary heart disease than those in the bottom quintile. Similarly, statin therapy resulted in the highest relative and absolute risk reductions in those at highest risk.

“There is ongoing debate over which individuals should be allocated statin therapy to prevent a first heart attack,” said the co-first author of the study, Nathan O. Stitziel, in a press release. “Some have said we should be treating more people, while others say we need to treat fewer. As an example of precision medicine, another approach is to identify people at high risk and preferentially prescribe statin therapy to those individuals. Genetics appears to be one way to identify high-risk patients.”

Categories: Uncategorized


You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

3 Responses to “Genetic Screening Test Could Identify People More Likely To Benefit From Statins”

  1. Tina Dobsevage, MD says:
    March 5, 2015 at 5:45 pm

    I would like this testing to be more widely available AND affordable. I think it would help me decide which of my patients with high cholesterol AND intolerant of statins need to be pushed to retry statins.

  2. William L Blanchet, MD says:
    March 5, 2015 at 6:35 pm

    Am I misreading this? A 70% increase from the lowest quartile to the highest is clinically insignificant. No help with decision making in half of the subjects and only a small fraction of the stratification we get from coronary calcium imaging which is inexpensive and readily available.

  3. Antonio H. Reis, Ph.D says:
    March 6, 2015 at 11:24 am

    I agree with Dr. Blanchet. In fact the absolute values of risk reduction must be considered to identify the extent of the benefits of statin therapy. Therefore, taking into account the data of the JUPITER Study (see Table 2 of the cited report in “Lancet”) to avoid an event, 100 people in the low genetic risk group would need to receive statin therapy during 6,6 years, in the intermediate risk group during 4,2 years, and in the high risk group during 2,5 years.
    Because any therapy must be benefic to the whole human being, and not only for a specific part of it, and due to known side-effects of statins I wonder if such a low absolute benefit of statin therapy is not annulled or even outshined by potential harms in other parts of the body?